The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis

Maha Abdalla, Harika Sabbineni, Roshini Prakash, Adviye Ergul, Susan C. Fagan, Payaningal R. Somanath

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGFβ-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1- / - mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGFβ-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGFβ-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1- / - mice lungs expressed less TSP1. Moreover, TSP1- / - mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.

Original languageEnglish (US)
Pages (from-to)4173-4188
Number of pages16
JournalBritish Journal of Pharmacology
Volume172
Issue number16
DOIs
StatePublished - Aug 1 2015

Fingerprint

triciribine
Pulmonary Fibrosis
Blood Vessels
Fibrosis
Interstitial Lung Diseases
Lung
Myofibroblasts
Sirolimus
Hypoxia
Pharmacology

ASJC Scopus subject areas

  • Pharmacology

Cite this

The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. / Abdalla, Maha; Sabbineni, Harika; Prakash, Roshini; Ergul, Adviye; Fagan, Susan C.; Somanath, Payaningal R.

In: British Journal of Pharmacology, Vol. 172, No. 16, 01.08.2015, p. 4173-4188.

Research output: Contribution to journalArticle

Abdalla, Maha ; Sabbineni, Harika ; Prakash, Roshini ; Ergul, Adviye ; Fagan, Susan C. ; Somanath, Payaningal R. / The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. In: British Journal of Pharmacology. 2015 ; Vol. 172, No. 16. pp. 4173-4188.
@article{93aac9aa60ed42b783a4afe4353ce69a,
title = "The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis",
abstract = "Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGFβ-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1- / - mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGFβ-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGFβ-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1- / - mice lungs expressed less TSP1. Moreover, TSP1- / - mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.",
author = "Maha Abdalla and Harika Sabbineni and Roshini Prakash and Adviye Ergul and Fagan, {Susan C.} and Somanath, {Payaningal R.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/bph.13203",
language = "English (US)",
volume = "172",
pages = "4173--4188",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "16",

}

TY - JOUR

T1 - The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis

AU - Abdalla, Maha

AU - Sabbineni, Harika

AU - Prakash, Roshini

AU - Ergul, Adviye

AU - Fagan, Susan C.

AU - Somanath, Payaningal R.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGFβ-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1- / - mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGFβ-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGFβ-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1- / - mice lungs expressed less TSP1. Moreover, TSP1- / - mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.

AB - Background and Purpose Interstitial lung disease accounts for a group of chronic and progressive disorders associated with severe pulmonary vascular remodelling, peripheral vascular rarefaction and fibrosis, thus limiting lung function. We have previously shown that Akt is necessary for myofibroblast differentiation, a critical event in organ fibrosis. However, the contributory role of the Akt-mTOR pathway in interstitial lung disease and the therapeutic benefits of targeting Akt and mTOR remain unclear. Experimental Approach We investigated the role of the Akt-mTOR pathway and its downstream molecular mechanisms in chronic hypoxia- and TGFβ-induced pulmonary vascular pruning and fibrosis in mice. We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice. Key Results Akt1- / - mice were protected from chronic hypoxia-induced peripheral vascular pruning. In contrast, hyperactivation of Akt1 induced focal fibrosis similar to TGFβ-induced fibrosis. Pharmacological inhibition of Akt, but not the Akt substrate mTOR, inhibited hypoxia- and TGFβ-induced pulmonary vascular rarefaction and fibrosis. Mechanistically, we found that Akt1 modulates pulmonary remodelling via regulation of thrombospondin1 (TSP1) expression. Hypoxic Akt1- / - mice lungs expressed less TSP1. Moreover, TSP1- / - mice were resistant to adMyrAkt1-induced pulmonary fibrosis. Conclusions and Implications Our study identified Akt1 as a novel target for the treatment of interstitial lung disease and provides preclinical data on the potential benefits of the Akt inhibitor triciribine for the treatment of interstitial lung disease.

UR - http://www.scopus.com/inward/record.url?scp=84937521014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937521014&partnerID=8YFLogxK

U2 - 10.1111/bph.13203

DO - 10.1111/bph.13203

M3 - Article

C2 - 26033700

AN - SCOPUS:84937521014

VL - 172

SP - 4173

EP - 4188

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 16

ER -